References
- World Health O. Global leprosy update, 2018. moving towards a leprosyfree world. Weekly epidemiological record (WER). 2019;Nos. 35/36(94):389–412.
- Cardoso FM, De Freitas MR, Escada TM, Nevares MT, Nascimento OJ. Late onset neuropathy in leprosy patients released from treatment: not all due to reactions? Lepr Rev. 2013;84(2):128–135.
- Alcais A, Mira M, Casanova JL, Schurr E, Abel L. Genetic dissection of immunity in leprosy. Curr Opin Immunol. 2005;17(1):44–48. doi:https://doi.org/10.1016/j.coi.2004.11.006.
- Mira MT. Genetic host resistance and susceptibility to leprosy. Microbes Infect. 2006;8(4):1124–1131. doi:https://doi.org/10.1016/j.micinf.2005.10.024.
- Sauer ME, Salomao H, Ramos GB, D'Espindula HR, et al. Genetics of leprosy: expected-and unexpected-developments and perspectives. Clin Dermatol. 2016;34(1):96–104. doi:https://doi.org/10.1016/j.clindermatol.2015.10.005.
- Moura RS, Penna GO, Fujiwara T, et al. Evaluation of a rapid serological test for leprosy classification using human serum albumin as the antigen carrier. J Immunol Methods. 2014;412:35–41. doi:https://doi.org/10.1016/j.jim.2014.06.014.
- Dupnik KM, Bair TB, Maia AO, et al. Transcriptional changes that characterize the immune reactions of leprosy. J Infect Dis. 2015;211(10):1658–1676. doi:https://doi.org/10.1093/infdis/jiu612.
- Monot M, Honore N, Garnier T, et al. Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet. 2009;41(12):1282–1289. doi:https://doi.org/10.1038/ng.477.
- Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature. 2001;409(6823):1007–1011. doi:https://doi.org/10.1038/35059006.
- Bochud PY, Hawn TR, Siddiqui MR, et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis. 2008;197(2):253–261. doi:https://doi.org/10.1086/524688.
- Kang TJ, Lee SB, Chae GT. A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine. 2002;20(2):56–62. doi:https://doi.org/10.1006/cyto.2002.1982.
- Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CG, Hill AV. Association of vitamin D receptor genotype with leprosy type. J Infect Dis. 1999;179(1):187–191. doi:https://doi.org/10.1086/314536.
- Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19(2):338–381. doi:https://doi.org/10.1128/CMR.19.2.338-381.2006.
- Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–273.
- Britton WJ, Lockwood DN. Leprosy. Lancet. 2004;363(9416):1209–1219. doi:https://doi.org/10.1016/S0140-6736(04)15952-7.
- Schlesinger LS, Horwitz MA. Phenolic glycolipid-1 of Mycobacterium leprae binds complement component C3 in serum and mediates phagocytosis by human monocytes. J Exp Med. 1991;174(5):1031–1038. doi:https://doi.org/10.1084/jem.174.5.1031.
- Schifferli JA, Morris SM, Dash A, Peters DK. Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis. Clin Exp Immunol. 1981;46(3):557–564.
- Manca C, Peixoto B, Malaga W, Guilhot C, Kaplan G. Modulation of the cytokine response in human monocytes by mycobacterium leprae phenolic glycolipid-1. J Interferon Cytokine Res. 2012;32(1):27–33. doi:https://doi.org/10.1089/jir.2011.0044.
- Teles RM, Graeber TG, Krutzik SR, Montoya D, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science. 2013;339(6126):1448–1453. doi:https://doi.org/10.1126/science.1233665.
- Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496(7446):445–455. doi:https://doi.org/10.1038/nature12034.
- Khanolkar-Young S, Snowdon D, Lockwood DN. Immunocytochemical localization of inducible nitric oxide synthase and transforming growth factor-beta (TGF-beta) in leprosy lesions. Clin Exp Immunol. 1998;113(3):438–442. doi:https://doi.org/10.1046/j.1365-2249.1998.00669.x.
- Bobosha K, Wilson L, van Meijgaarden KE, et al. T-cell regulation in lepromatous leprosy. PLoS Negl Trop Dis. 2014;8(4):e2773. doi:https://doi.org/10.1371/journal.pntd.0002773.
- Moura DF, de Mattos KA, Amadeu TP, et al. CD163 favors Mycobacterium leprae survival and persistence by promoting anti-inflammatory pathways in lepromatous macrophages. Eur J Immunol. 2012;42(11):2925–2936. doi:https://doi.org/10.1002/eji.201142198.
- Caldwell RB, Toque HA, Narayanan SP, Caldwell RW. Arginase: an old enzyme with new tricks. Trends Pharmacol Sci. 2015;36(6):395–405. doi:https://doi.org/10.1016/j.tips.2015.03.006.
- Chistiakov DA, Bobryshev YV, Orekhov AN. Changes in transcriptome of macrophages in atherosclerosis. J Cell Mol Med. 2015;19(6):1163–1173. doi:https://doi.org/10.1111/jcmm.12591.
- Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol. 2012;3:44. doi:https://doi.org/10.3389/fphys.2012.00044.
- De Paoli F, Staels B, Chinetti-Gbaguidi G. Macrophage phenotypes and their modulation in atherosclerosis. Circ J. 2014;78(8):1775–1781. doi:https://doi.org/10.1253/circj.cj-14-0621.
- de Sousa JR, Lucena Neto FD, Sotto MN, Quaresma JAS. Immunohistochemical characterization of the M4 macrophage population in leprosy skin lesions. BMC Infect Dis. 2018;18(1):576. doi:https://doi.org/10.1186/s12879-018-3478-x.
- Charrad R, Berraïes A, Hamdi B, Ammar J, Hamzaoui K, Hamzaoui A. Anti-inflammatory activity of IL-37 in asthmatic children: correlation with inflammatory cytokines TNF-α, IL-β, IL-6 and IL-17A. Immunobiology. 2016;221(2):182–187. doi:https://doi.org/10.1016/j.imbio.2015.09.009.
- Ding VA, Zhu Z, Mantz AA, et al. The role of IL-37 in non-cancerous diseases. Pathol Oncol Res. 2017;23(3):463–470. doi:https://doi.org/10.1007/s12253-016-0137-7.
- Huang Z, Gao C, Chi X, et al. IL-37 expression is upregulated in patients with tuberculosis and induces macrophages towards an M2-like phenotype. Scand J Immunol. 2015;82(4):370–379. doi:https://doi.org/10.1111/sji.12326.
- Montoya D, Cruz D, Teles RM, et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe. 2009;6(4):343–353. doi:https://doi.org/10.1016/j.chom.2009.09.002.
- Krutzik SR, Tan B, Li H, et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med. 2005;11(6):653–660. doi:https://doi.org/10.1038/nm1246.
- Kang TJ, Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol. 2001;31(1):53–58. doi:https://doi.org/10.1111/j.1574-695X.2001.tb01586.x.
- Hirai KE, Aarao TL, Silva LM, et al. Langerhans cells (CD1a and CD207), dermal dendrocytes (FXIIIa) and plasmacytoid dendritic cells (CD123) in skin lesions of leprosy patients. Microb Pathog. 2016;91:18–25. doi:https://doi.org/10.1016/j.micpath.2015.11.013.
- Spierings E, De Boer T, Zulianello L, Ottenhoff TH. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. Immunol Cell Biol. 2000;78(4):349–355. doi:https://doi.org/10.1046/j.1440-1711.2000.00939.x.
- Spierings E, de Boer T, Wieles B, Adams LB, Marani E, Ottenhoff TH. Mycobacterium leprae-specific, HLA class II-restricted killing of human Schwann cells by CD4+ Th1 cells: a novel immunopathogenic mechanism of nerve damage in leprosy. J Immunol. 2001;166(10):5883–5888. doi:https://doi.org/10.4049/jimmunol.166.10.5883.
- Andrade PR, Jardim MR, da Silva AC, et al. Inflammatory cytokines are involved in focal demyelination in Leprosy Neuritis. J Neuropathol Exp Neurol. 2016;75(3):272–283. doi:https://doi.org/10.1093/jnen/nlv027.
- Amin J, Boche D, Rakic S. What do we know about the inflammasome in humans? Brain Pathol. 2017;27(2):192–204. doi:https://doi.org/10.1111/bpa.12479.
- Zamboni DS, Lima-Junior DS. Inflammasomes in host response to protozoan parasites. Immunol Rev. 2015;265(1):156–171. doi:https://doi.org/10.1111/imr.12291.
- Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16(7):407–420. doi:https://doi.org/10.1038/nri.2016.58.
- Silva LM, de Sousa JR, Hirai KE, et al. The inflammasome in leprosy skin lesions: an immunohistochemical evaluation. Infect Drug Resist. 2018;11:2231–2240. doi:https://doi.org/10.2147/IDR.S172806.
- Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1991;254(5029):277–279. doi:https://doi.org/10.1126/science.1925582.
- Bleharski JR, Li H, Meinken C, et al. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science. 2003;301(5639):1527–1530. doi:https://doi.org/10.1126/science.1087785.
- Sampaio LH, Sousa AL, Barcelos MC, Reed SG, Stefani MM, Duthie MS. Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy. Eur J Clin Microbiol Infect Dis. 2012;31(7):1443–1451. doi:https://doi.org/10.1007/s10096-011-1462-0.
- Silva LM, Hirai KE, de Sousa JR, et al. Immunohistochemical analysis of the expression of cellular transcription NFκB (p65), AP-1 (c-Fos and c-Jun), and JAK/STAT in leprosy . Hum Pathol. 2015;46(5):746–752. doi:https://doi.org/10.1016/j.humpath.2015.01.015.
- Modlin RL. Th1-Th2 paradigm: insights from leprosy. J Invest Dermatol. 1994;102(6):828–832. doi:https://doi.org/10.1111/1523-1747.ep12381958.
- Rendini T, Levis W. Leprosy is teaching us the immunopathogenesis of inflammatory skin disease. J Allergy Clin Immunol. 2015;136(6):1707. doi:https://doi.org/10.1016/j.jaci.2015.08.029.
- Magombedze G, Reddy PB, Eda S, Ganusov VV. Cellular and population plasticity of helper CD4(+) T cell responses. Front Physiol. 2013;4:206. doi:https://doi.org/10.3389/fphys.2013.00206.
- Zhou W, Zhang F, Aune TM. Either IL-2 or IL-12 is sufficient to direct Th1 differentiation by nonobese diabetic T cells. J Immunol. 2003;170(2):735–740. doi:https://doi.org/10.4049/jimmunol.170.2.735.
- Walker SL, Lockwood DN. The clinical and immunological features of leprosy. Br Med Bull. 2006;77–78:103–121. doi:https://doi.org/10.1093/bmb/ldl010.
- de Sousa JR, Pagliari C, de Almeida DSM, et al. Th9 cytokines response and its possible implications in the immunopathogenesis of leprosy. J Clin Pathol. 2017;70(6):521–527. doi:https://doi.org/10.1136/jclinpath-2016-204110.
- de Sousa JR, Quaresma JAS. The role of T helper 25 (Th25) cells in the immune response to M. leprae. J Am Acad Dermatol. 2017;78(5):1009–1011. doi:https://doi.org/10.1016/j.jaad.2017.11.025.
- Tarique M, Saini C, Naqvi RA, Khanna N, Sharma A, Rao DN. IL-12 and IL-23 modulate plasticity of FoxP3+ regulatory T cells in human Leprosy. Mol Immunol. 2017;83:72–81. doi:https://doi.org/10.1016/j.molimm.2017.01.008.
- Amedei A, Munari F, Bella CD, et al. Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Intern Emerg Med. 2014;9(3):303–309. doi:https://doi.org/10.1007/s11739-012-0867-9.
- Attia EAS, Abdallah M, El-Khateeb E, et al. Serum Th17 cytokines in leprosy: correlation with circulating CD4(+) CD25 (high)FoxP3 (+) T-regs cells, as well as down regulatory cytokines. Arch Dermatol Res. 2014;306(9):793–801. doi:https://doi.org/10.1007/s00403-014-1486-2.
- Saini C, Ramesh V, Nath I. CD4+ Th17 cells discriminate clinical types and constitute a third subset of non Th1, Non Th2 T cells in human leprosy. PLoS Negl Trop Dis. 2013;7(7):e2338. doi:https://doi.org/10.1371/journal.pntd.0002338.
- Martiniuk F, Giovinazzo J, Tan AU, et al. Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. J Drugs Dermatol. 2012;11(5):626–630.
- Aarão TL, de Sousa JR, Botelho BS, Fuzii HT, Quaresma JA. Correlation between nerve growth factor and tissue expression of IL-17 in leprosy. Microb Pathog. 2016;90:64–68. doi:https://doi.org/10.1016/j.micpath.2015.11.019.
- Kong Q, Wu W, Yang F, et al. Increased expressions of IL-22 and Th22 cells in the coxsackievirus B3-Induced mice acute viral myocarditis. Virol J. 2012;9:232. doi:https://doi.org/10.1186/1743-422X-9-232.
- Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573–3585.
- Furuzawa-Carballeda J, Bostock IC, Lima G, et al. Immunophenotyping of peripheral immunoregulatory as well as Th17A and Th22 cell subpopulations in kidney transplant recipients under belatacept or cyclosporine treatment. Transpl Immunol. 2014;30(2–3):107–113. doi:https://doi.org/10.1016/j.trim.2014.02.002.
- Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857–863. doi:https://doi.org/10.1038/ni.1767.
- Fischer MK, Myer KA, Que SK, et al. Pseudoepitheliomatous hyperplasia and transepidermal elimination in lepromatous leprosy: does T-cell plasticity play a role? J Drugs Dermatol. 2012;11(10):1232–1235.
- de Lima Silveira E, de Sousa JR, de Sousa Aarao TL, et al. New immunologic pathways in the pathogenesis of leprosy: role for Th22 cytokines in the polar forms of the disease. J Am Acad Dermatol. 2015;72(4):729–730. doi:https://doi.org/10.1016/j.jaad.2014.11.023.
- de Sousa JR, de Sousa RPM, de Souza Aarão TL, Dias LB, Oliveira Carneiro FR, Simões Quaresma JA. Response of iNOS and its relationship with IL-22 and STAT3 in macrophage activity in the polar forms of leprosy. Acta Trop. 2017;171:74–79. doi:https://doi.org/10.1016/j.actatropica.2017.03.016.
- de Sousa JR, de Sousa RPM, Aarão T. L d S, et al. In situ expression of M2 macrophage subpopulation in leprosy skin lesions. Acta Trop. 2016;157:108–114. doi:https://doi.org/10.1016/j.actatropica.2016.01.008.
- Sakaguchi S, Powrie F. Emerging challenges in regulatory T cell function and biology. Science. 2007;317(5838):627–629. doi:https://doi.org/10.1126/science.1142331.
- Quaresma JAS, Esteves PC, de Sousa Aarão TL, de Sousa JR, da Silva Pinto D, Fuzii HT. Apoptotic activity and Treg cells in tissue lesions of patients with leprosy. Microb Pathog. 2014;76:84–88. doi:https://doi.org/10.1016/j.micpath.2014.07.005.
- Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–564. doi:https://doi.org/10.1146/annurev.immunol.25.022106.141623.
- Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7(11):875–888. doi:https://doi.org/10.1038/nri2189.
- Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636–645. doi:https://doi.org/10.1016/j.immuni.2009.04.010.
- Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA. The development and function of regulatory T cells. Cell Mol Life Sci. 2009;66(16):2603–2622. doi:https://doi.org/10.1007/s00018-009-0026-2.
- Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–787. doi:https://doi.org/10.1016/j.cell.2008.05.009.
- Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061. doi:https://doi.org/10.1126/science.1079490.
- Palermo ML, Pagliari C, Trindade MAB, et al. Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am J Trop Med Hyg. 2012;86(5):878–883. doi:https://doi.org/10.4269/ajtmh.2012.12-0088.
- Fernandes C, Gonçalves HS, Cabral PB, Pinto HC, Pinto MIM, Câmara LMC. Increased frequency of CD4 and CD8 regulatory T cells in individuals under 15 years with multibacillary leprosy. PLoS One. 2013;8(11):e79072. doi:https://doi.org/10.1371/journal.pone.0079072.
- Kumar S, Naqvi RA, Ali R, Rani R, Khanna N, Rao DN. FoxP3 provides competitive fitness to CD4+CD25+T cells in leprosy patients via transcriptional regulation . Eur J Immunol. 2014;44(2):431–439. doi:https://doi.org/10.1002/eji.201343649.
- Kumar S, Naqvi RA, Ali R, Rani R, Khanna N, Rao DN. CD4 + CD25+ T regs with acetylated FoxP3 are associated with immune suppression in human leprosy. Mol Immunol. 2013;56(4):513–520. doi:https://doi.org/10.1016/j.molimm.2013.04.015.
- Saini C, Ramesh V, Nath I. Increase in TGF-beta secreting CD4(+)CD25(+) FOXP3(+) T regulatory cells in anergic lepromatous leprosy patients. PLoS Negl Trop Dis. 2014;8(1):e2639. doi:https://doi.org/10.1371/journal.pntd.0002639.
- Sadhu S, Khaitan BK, Joshi B, Sengupta U, Nautiyal AK, Mitra DK. Reciprocity between regulatory T cells and Th17 cells: relevance to polarized immunity in leprosy. PLoS Negl Trop Dis. 2016;10(1):e0004338. doi:https://doi.org/10.1371/journal.pntd.0004338.
- Abdallah M, Attia EAS, Saad AA, et al. Serum Th1/Th2 and macrophage lineage cytokines in leprosy; correlation with circulating CD4(+) CD25(high) FoxP3(+) T-regs cells. Exp Dermatol. 2014;23(10):742–747. doi:https://doi.org/10.1111/exd.12529.
- Chaves AT, Ribeiro-Junior AF, Lyon S, et al. Regulatory T cells: friends or foe in human Mycobacterium leprae infection? Immunobiology. 2018;223(4–5):397–404. doi:https://doi.org/10.1016/j.imbio.2017.11.002.
- Quaresma JA, Aarao TL, Sousa JR, et al. T-helper 17 cytokines expression in leprosy skin lesions. Br J Dermatol. 2015;173(2):565–567. doi:https://doi.org/10.1111/bjd.13608.
- Tarique M, Saini C, Naqvi RA, Khanna N, Rao DN. Increased IL-35 producing Tregs and CD19(+)IL-35(+) cells are associated with disease progression in leprosy patients. Cytokine. 2017;91:82–88. doi:https://doi.org/10.1016/j.cyto.2016.12.011.
- Souza J, Sousa JR, Hirai KE, et al. E-selectin and P-selectin expression in endothelium of leprosy skin lesions. Acta Trop. 2015;149:227–231. doi:https://doi.org/10.1016/j.actatropica.2015.06.002.
- de Sousa J, Sousa Aarao TL, Rodrigues de Sousa J, et al. Endothelium adhesion molecules ICAM-1, ICAM-2, VCAM-1 and VLA-4 expression in leprosy. Microb Pathog. 2017;104:116–124. doi:https://doi.org/10.1016/j.micpath.2017.01.021.
- Goulart IM, Penna GO, Cunha G. Immunopathology of leprosy: the complexity of the mechanisms of host immune response to Mycobacterium leprae. Rev Soc Bras Med Trop. 2002;35(4):365–375. doi:https://doi.org/10.1590/s0037-86822002000400014.
- Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol. 2008;29(1):34–40. doi:https://doi.org/10.1016/j.it.2007.10.004.
- Ochoa MT, Teles R, Haas BE, et al. A role for interleukin-5 in promoting increased immunoglobulin M at the site of disease in leprosy. Immunology. 2010;131(3):405–414. doi:https://doi.org/10.1111/j.1365-2567.2010.03314.x.
- Motta AC, Pereira KJ, Tarquinio DC, Vieira MB, Miyake K, Foss NT. Leprosy reactions: coinfections as a possible risk factor. Clinics (Sao Paulo). 2012;67(10):1145–1148. doi:https://doi.org/10.6061/clinics/2012(10)05.
- Sousa AL, Fava VM, Sampaio LH, et al. Genetic and immunological evidence implicates interleukin 6 as a susceptibility gene for leprosy type 2 reaction. J Infect Dis. 2012;205(9):1417–1424. doi:https://doi.org/10.1093/infdis/jis208.
- Mastrangelo G, Marcer G, Cegolon L, et al. How to prevent immunological reactions in leprosy patients and interrupt transmission of Mycobacterium leprae to healthy subjects: two hypotheses. Med Hypotheses. 2008;71(4):551–563. doi:https://doi.org/10.1016/j.mehy.2008.05.016.
- Walker SL, Balagon M, Darlong J, Erythema Nodosum Leprosum International STudy Group, et al. ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema Nodosum Leprosum. PLoS Negl Trop Dis. 2015;9(9):e0004065. doi:https://doi.org/10.1371/journal.pntd.0004065.
- Walker SL, Nicholls PG, Butlin CR, et al. Development and validation of a severity scale for leprosy type 1 reactions. PLoS Negl Trop Dis. 2008;2(12):e351. doi:https://doi.org/10.1371/journal.pntd.0000351.
- Chowdhry S, Shukla A, D'Souza P, Dhali T, Jaiswal P. Treatment of severe refractory erythema nodosum leprosum with tumor necrosis factor inhibitor Etanercept. Int J Mycobacteriol. 2016;5(2):223–225. doi:https://doi.org/10.1016/j.ijmyco.2016.02.002.
- Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DN. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun. 2001;69(5):3413–3417. doi:https://doi.org/10.1128/IAI.69.5.3413-3417.2001.
- Khanolkar-Young S, Rayment N, Brickell PM, et al. Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol. 1995;99(2):196–202. doi:https://doi.org/10.1111/j.1365-2249.1995.tb05532.x.
- Kirkaldy AA, Musonda AC, Khanolkhar-Young S, Suneetha S, Lockwood DN. Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol. 2003;134(3):447–453. doi:https://doi.org/10.1111/j.1365-2249.2003.02306.x.
- Misch EA, Berrington WR, Vary JC, Jr, Hawn TR. Leprosy and the human genome. Microbiol Mol Biol Rev. 2010;74(4):589–620. doi:https://doi.org/10.1128/MMBR.00025-10.
- Polycarpou A, Walker SL, Lockwood DN. A systematic review of immunological studies of Erythema nodosum leprosum. Front Immunol. 2017;8:233. doi:https://doi.org/10.3389/fimmu.2017.00233.
- Wemambu SN, Turk JL, Waters MF, Rees RJ. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet. 1969;2(7627):933–935. doi:https://doi.org/10.1016/S0140-6736(69)90592-3.
- Lee DJ, Li H, Ochoa MT, et al. Integrated pathways for neutrophil recruitment and inflammation in leprosy. J Infect Dis. 2010;201(4):558–569. doi:https://doi.org/10.1086/650318.
- Iyer A, Hatta M, Usman R, et al. Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol. 2007;150(2):210–216. doi:https://doi.org/10.1111/j.1365-2249.2007.03485.x.
- Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. 2006;355(7):739. doi:https://doi.org/10.1056/NEJMc052955.
- Ramien ML, Wong A, Keystone JS. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis. 2011;52(5):e133–e135. doi:https://doi.org/10.1093/cid/ciq213.
- Schmitz V, Prata RB, Barbosa MG, et al. Expression of CD64 on circulating neutrophils favoring systemic inflammatory status in erythema nodosum leprosum. PLoS Negl Trop Dis. 2016;10(8):e0004955. doi:https://doi.org/10.1371/journal.pntd.0004955.
- Buckle AM, Hogg N. The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors. J Immunol. 1989;143(7):2295–2301.
- Voorend CG, Post EB. A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction. PLoS Negl Trop Dis. 2013;7(10):e2440 doi:https://doi.org/10.1371/journal.pntd.0002440.
- Wallach D, Cottenot F, Bach MA. Imbalances in T cell subpopulations in lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1982;50(3):282–290.
- Mshana RN, Haregewoin A, Belehu A. Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. J Clin Immunol. 1982;2(2):69–74. doi:https://doi.org/10.1007/BF00916889.
- Narayanan RB, Laal S, Sharma AK, Bhutani LK, Nath I. Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Clin Exp Immunol. 1984;55(3):623–628.
- Wallach D, Flageul B, Cottenot F, Bach MA. Patients with erythema nodosum leprosum lack T-suppressor cells. Arch Dermatol. 1985;121(11):1379.
- Hussain T, Kulshreshtha KK, Yadav VS, Katoch K. CD4+, CD8+, CD3+ cell counts and CD4+/CD8+ ratio among patients with mycobacterial diseases (leprosy, tuberculosis), HIV infections, and normal healthy adults: a comparative analysis of studies in different regions of India. J Immunoassay Immunochem. 2015;36(4):420–443. doi:https://doi.org/10.1080/15321819.2014.978082.
- Vieira AP, Trindade MA, Pagliari C, Avancini J, et al. Development of Type 2, but not Type 1, leprosy reactions is associated with a severe reduction of circulating and in situ regulatory T-cells. Am J Trop Med Hyg. 2016;94(4):721–727. doi:https://doi.org/10.4269/ajtmh.15-0673.
- de Azevedo MP, de Melo PH. A comparative study of the complementary activity of serum in the polar forms of leprosy and in the leprosy reaction. Int J Lepr Other Mycobact Dis. 1966;34(1):34–38.
- Lange K, Wasserman E, Slobody LB. The significance of serum complement levels for the diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus. Ann Intern Med. 1960;53:636–646. doi:https://doi.org/10.7326/0003-4819-53-4-636.
- Ohi H, Tamano M. Decreased apolipoprotein levels are associated with decreased complement levels in acute glomerulonephritis. Nephron. 2001;88(4):389–390. doi:https://doi.org/10.1159/000046028.
- de Messias IJ, Reis A, Brenden M, Queiroz-Telles F, Mauff G. Association of major histocompatibility complex class III complement components C2, BF, and C4 with Brazilian paracoccidioidomycosis. Complement Inflamm. 1991;8(5–6):288–293. doi:https://doi.org/10.1159/000463198.
- Grevink ME, Horst G, Limburg PC, Kallenberg CG, Bijl M. Levels of complement in sera from inactive SLE patients, although decreased, do not influence in vitro uptake of apoptotic cells. J Autoimmun. 2005;24(4):329–336. doi:https://doi.org/10.1016/j.jaut.2005.03.004.
- Hauptmann G, Tappeiner G, Schifferli JA. Inherited deficiency of the fourth component of human complement. Immunodefic Rev. 1988;1(1):3–22.
- Bjorvatn B, Barnetson RS, Kronvall G, Zubler RH, Lambert PH. Immune complexes and complement hypercatabolism in patients with leprosy. Clin Exp Immunol. 1976;26(3):388–396.
- Lahiri R, Sandoval FG, Krahenbuhl JL, Shannon EJ. Activation of complement by Mycobacterium leprae requires disruption of the bacilli. Lepr Rev. 2008;79(3):311–314.
- Duthie MS, Hay MN, Morales CZ, et al. Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis. Clin Vaccine Immunol. 2010;17(2):298–303. doi:https://doi.org/10.1128/CVI.00400-09.
- Duthie MS, Goto W, Ireton GC, et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol. 2007;14(11):1400–1408. doi:https://doi.org/10.1128/CVI.00299-07.
- Buhrer-Sekula S. PGL-I leprosy serology. Rev Soc Bras Med Trop. 2008;41 (Suppl 2):3–5.
- Wen Y, You YG, Yuan LC, et al. Evaluation of novel tools to facilitate the detection and characterization of leprosy patients in China. Biomed Res Int. 2014;2014:371828. doi:https://doi.org/10.1155/2014/371828.
- Hunter SW, Brennan PJ. A novel phenolic glycolipid from Mycobacterium leprae possibly involved in immunogenicity and pathogenicity. J Bacteriol. 1981;147(3):728–735. doi:https://doi.org/10.1128/JB.147.3.728-735.1981.
- Buhrer-Sekula S, Smits HL, Gussenhoven GC, et al. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol. 2003;41(5):1991–1995. doi:https://doi.org/10.1128/jcm.41.5.1991-1995.2003.
- Moura RS, Calado KL, Oliveira ML, Buhrer-Sekula S. Leprosy serology using PGL-I: a systematic review. Rev Soc Bras Med Trop. 2008;41 (Suppl 2):11–18. doi:https://doi.org/10.1590/s0037-86822008000700004.
- Iyer AM, Mohanty KK, van Egmond D, et al. Leprosy-specific B-cells within cellular infiltrates in active leprosy lesions. Hum Pathol. 2007;38(7):1065–1073. doi:https://doi.org/10.1016/j.humpath.2006.12.017.
- Marzano AV, Tosi D, Cusini M, Nunzi E, Massone C, Crosti C. Facial reversal reaction: a dermatological emergency. J Dermatol. 2012;39(2):203–205. doi:https://doi.org/10.1111/j.1346-8138.2011.01248.x.
- Roche PW, Theuvenet WJ, Britton WJ. Risk factors for type-1 reactions in borderline leprosy patients. Lancet. 1991;338(8768):654–657. doi:https://doi.org/10.1016/0140-6736(91)91232-j.
- Antunes DE, Araujo S, Ferreira GP, et al. Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy. Mem Inst Oswaldo Cruz. 2013;108(7):901–908. doi:https://doi.org/10.1590/0074-0276130222.
- Brito M d F d M, Ximenes RAA, Gallo MEN, Bührer-Sékula S. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy. Rev Soc Bras Med Trop. 2008;41 (Suppl 2):67–72. doi:https://doi.org/10.1590/s0037-86822008000700014.
- Hungria EM, Oliveira RM, Penna GO, et al. Can baseline ML flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil. Infect Dis Poverty. 2016;5(1):110 doi:https://doi.org/10.1186/s40249-016-0203-0.
- Duthie MS, Ireton GC, Kanaujia GV, et al. Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis. Clin Vaccine Immunol. 2008;15(10):1590–1597. doi:https://doi.org/10.1128/CVI.00168-08.
- Duthie MS, Hay MN, Rada EM, et al. Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. Eur J Clin Microbiol Infect Dis. 2011;30(10):1257–1265. doi:https://doi.org/10.1007/s10096-011-1221-2.
- Duthie MS, Raychaudhuri R, Tutterrow YL, et al. A rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugate. Diagn Microbiol Infect Dis. 2014;79(2):233–239. doi:https://doi.org/10.1016/j.diagmicrobio.2014.02.006.
- da Conceicao Oliveira Coelho Fabri A, Carvalho AP, Araujo S, et al. Antigen-specific assessment of the immunological status of various groups in a leprosy endemic region. BMC Infect Dis. 2015;15:218. doi:https://doi.org/10.1186/s12879-015-0962-4.
- Hungria EM, Buhrer-Sekula S, de Oliveira RM, et al. Leprosy reactions: the predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR). PLoS Negl Trop Dis. 2017;11(2):e0005396. doi:https://doi.org/10.1371/journal.pntd.0005396.
- Arantes CK, Garcia MLR, Filipe MS, et al. Avaliação dos serviços de saúde em relação ao diagnóstico precoce da hanseníase. Epidemiol Serv Saúde. 2010;19(2):155–164.
- Wang J, Wang Z, Yao Y, et al. The fibroblast growth factor-2 arrests Mycobacterium avium sp. paratuberculosis growth and immunomodulates host response in macrophages. Tuberculosis (Edinb)). 2015;95(4):505–514. doi:https://doi.org/10.1016/j.tube.2015.04.006.